77.56
0.77%
+0.59
시간 외 거래:
77.56
Biomarin Pharmaceutical Inc. (BMRN) 재무 분석
손익 계산서
분기별
*모든 숫자는 백만 단위입니다.
기간 종료일 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 |
기간 | 3개월 | 3개월 | 3개월 | 3개월 | 3개월 |
Revenues |
11.16%
646.21
|
581.33 | 595.27 | 596.41 | 537.54 |
Cost Of Revenue |
8.60%
135.48
|
124.75 | 128.08 | 126.55 | 127.29 |
Gross Profit |
11.86%
510.73
|
456.58 | 467.19 | 469.87 | 410.25 |
Operating Expenses
|
15.22%
496.51
|
430.92 | 408.32 | 410.52 | 434.75 |
Interest Income/Expense |
61.37%
6.098
|
3.779 | 3.755 | 3.703 | 3.626 |
Benefits Costs and Expenses |
16.16%
626.88
|
539.66 | 524.47 | 539.66 | 555.10 |
Costs And Expenses |
13.73%
631.99
|
555.67 | 536.40 | 537.07 | 562.04 |
Operating Income/Loss |
44.59%
14.22
|
25.66 | 58.87 | 59.35 | -24.50 |
Income/Loss From Continuing Operations Before Tax |
53.62%
19.33
|
41.67 | 70.81 | 56.76 | -17.56 |
Income Tax Expense/Benefit, Deferred |
65.31%
-24.84
|
-15.03 | 1.252 | -6.36 | -51.34 |
Income Tax Expense/Benefit |
181.18%
-1.048
|
1.291 | 14.77 | 5.905 | -17.31 |
Income/Loss From Continuing Operations After Tax |
49.54%
20.38
|
40.38 | 56.04 | 50.85 | -0.249 |
Net Income/Loss
|
49.54%
20.38
|
40.38 | 56.04 | 50.85 | -0.249 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
99.88%
0.217
|
188.22 | 187.95 | 186.67 | 0.257 |
Diluted Average Shares |
101.80%
-3.447
|
191.17 | 195.00 | 194.36 | -3.289 |
Basic Earnings Per Share |
47.62%
0.11
|
0.21 | 0.30 | 0.27 | -0.01 |
Diluted Earnings Per Share |
52.38%
0.10
|
0.21 | 0.29 | 0.27 | - |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
자본화:
|
볼륨(24시간):